TriSalus Life Sciences Warrant
TLSIW
19 hedge funds and large institutions have $1.2M invested in TriSalus Life Sciences Warrant in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 6 closing their positions.
650% more capital invested
Capital invested by funds: $160K → $1.2M (+$1.04M)
17% less funds holding
Funds holding: 23 → 19 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$16.6K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9 |
Top Sellers
TLSIW Hedge Fund Activity: Q3 2023 in Review
19 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences Warrant (TLSIW) for Q3 2023, worth a combined $1.2M — up 650% from $160K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TLSIW and 2 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was Shaolin Capital Management, opening a new position worth an estimated $16.6K. The largest seller was Magnetar Financial, cutting an estimated $70.8K.
- 19 institutional investors held TriSalus Life Sciences Warrant (TLSIW) as of Q3 2023, down from 23 in Q2 2023.
- Funds reported $1.2M of TriSalus Life Sciences Warrant stock for Q3 2023, up 650% quarter-over-quarter.
- 2 funds opened new TriSalus Life Sciences Warrant positions in Q3 2023 and 6 closed out, a net change of -4 holders.
- The largest TriSalus Life Sciences Warrant buyer in Q3 2023 was Shaolin Capital Management, an estimated $16.6K added.
- The largest TriSalus Life Sciences Warrant seller in Q3 2023 was Magnetar Financial, an estimated $70.8K sold.
Based on aggregated 13F filings for Q3 2023.